Psychedelics Research Inclusion Gains Bipartisan Momentum in Must-Pass Defense Bill
In a landmark development, a key psychedelics research amendment finds celebration among bipartisan congressional lawmakers as it gets included in the must-pass defense bill currently on the House floor. Representatives Dan Crenshaw (R-TX), Alexandria Ocasio-Cortez (D-NY), and Lou Correa (D-CA) held a press conference to discuss the recent progress and their next steps in advocating for this groundbreaking measure.
The amendment, which mirrors a standalone bill introduced by Rep. Crenshaw last month, still requires some refinements, as staff from the prior panel had made changes to the funding and clinical trial requirements within the National Defense Authorization Act (NDAA). Despite more than a dozen drug policy reform amendments being blocked from floor consideration, the defense secretary would be mandated, under the current form of the NDAA, to conduct clinical studies into the therapeutic benefits of psychedelics for service members experiencing PTSD, traumatic brain injury, or chronic traumatic encephalopathy.
Psilocybin, MDMA, ibogaine, or DMT would be the substances involved in the clinical studies, and the defense secretary must submit a report with trial findings to lawmakers within one year of the legislation’s enactment.
Rep. Crenshaw shared that he has received commitments from House Speaker Kevin McCarthy (R-CA) to collaborate in restoring the original language during bicameral conference negotiations with the Senate or through a standalone bill. This rare bipartisan unity around psychedelics stems from the realization that these therapies show promising results, with studies indicating significant reductions in PTSD symptoms and vast potential in other drugs.
Congresswoman Ocasio-Cortez also reflected on the progress made in advancing psychedelic research and its applications for PTSD treatment. While celebrating the legislative success, she acknowledges that there may be challenges in the Senate. Encouraging public engagement, she urges citizens to voice their support for this crucial legislation by reaching out to their senators.
Congressman Correa, as the founding co-chair of the congressional psychedelics caucus, stressed the importance of the measure not only for veterans but for society as a whole. He condemned the stigma associated with medical solutions that were once hindered by the failed war on drugs and the ongoing cost to society.
Additionally, Rep. Correa and Rep. Jack Bergman (R-MI) applauded the recent draft guidance issued by the Food and Drug Administration (FDA) on researching psychedelics, like psilocybin and MDMA, which provides a framework for future studies to develop psychedelic medicines. The FDA’s move has garnered support from lawmakers and signifies further progress in the field.
Last month, the National Institute on Drug Abuse (NIDA), under the guidance of HHS Secretary Xavier Becerra, called for research into the impact of evolving laws surrounding psychedelics and their potential role in treating drug addiction. NIDA’s call aligns with the broader effort to explore the beneficial aspects of psychedelics in various medical contexts, attracting funding support for relevant studies.
With the momentum growing and lawmakers from diverse political spectrums coming together, the path to expand psychedelics research inclusion seems increasingly promising. As the defense bill advances and the Senate debate approaches, the nation watches eagerly to witness the potential breakthrough in the field of psychedelic medicine.
